The company believes it can provide tests to predict patients' responsiveness to specific drugs akin to the molecular diagnostics that have now swelled the oncology space.
The company's technology uses a drop of blood applied to a biochip to provide a "complete panel" of diagnostic test results within 15 minutes.
The deal is an extension of an existing agreement involving the license of 14 patents to develop a platform for detecting traumatic brain injury.
The researchers aim to offer the half-hour diagnostic assay for use during neurosurgery to help clinicians pursue the best treatment for patients with gliomas.
The researchers have prospectively validated a disposable cartridge-based microfluidic assay by obtaining results using fine-needle aspirates in 40 patients.
The firm said that its technology enables the detection of rare DNA variants with high accuracy to enable liquid biopsy diagnosis and treatments for multiple diseases.
The device being developed will interpret the scattered patterns of light that has passed through the body to enable cellular-level imaging and will compete with biopsies and blood tests.
The portable device runs an isothermal amplification assay to detect genetic material from strains of tuberculosis in resource limited areas.
One firm, Exosome Diagnostics, is working to streamline payor coverage for a commercial test, and researchers are simultaneously developing promising ways to isolate exosomes.
The similar analytic performance of LDTs and FDA-approved tests informs the ongoing debate about the regulation of in vitro testing.